Novavax, Inc. (NVAX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$10.22-1.16%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NVAX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 413.8 | 1,123.5 | 682.2 | 983.7 | 1,981.9 | 1,146.3 | 475.6 | 18.7 | 34.3 | 31.2 | 15.4 | 36.3 | 30.7 | 20.9 | 22.1 | — |
| Total Revenues | 413.8 | 1,123.5 | 682.2 | 983.7 | 1,981.9 | 1,146.3 | 475.6 | 18.7 | 34.3 | 31.2 | 15.4 | 36.3 | 30.7 | 20.9 | 22.1 | — |
| Cost of Revenues | 88.5 | 73.0 | 202.7 | 343.8 | 902.6 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 121.2 | 157.5 | 337.2 | 468.9 | 488.7 | — | — | — | — | — | — | — | — | — | — | — |
| R&D Expenses | 340.3 | 342.3 | 391.2 | 737.5 | 1,235.3 | 2,534.5 | 747.0 | 113.8 | 173.8 | 168.4 | 237.9 | 162.6 | 94.4 | 58.5 | 26.9 | 18.4 |
| Operating Income | (234.1) | 452.8 | (248.9) | (566.5) | (644.7) | (1,686.6) | (416.7) | (120.6) | (173.9) | (171.7) | (269.1) | (157.2) | (83.7) | (52.4) | (29.7) | (21.6) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 22.5 | 20.1 | 14.4 | 19.9 | 21.1 | 15.1 | 13.6 | 13.6 | 14.1 | 13.0 | 0.2 | 0.2 | 0.2 | 0.0 | 0.0 |
| Interest & Investment Income | 28.5 | 29.5 | — | 20.1 | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Interest Expenses | — | — | — | (5.7) | — | — | — | — | — | — | — | — | — | — | — | — |
| Asset Writedown | — | — | 4.1 | 10.1 | 0.0 | 0.0 | — | — | — | — | — | — | — | 0.4 | 0.4 | — |
| EBT, Incl. Unusual Items | (245.3) | 442.2 | (176.6) | (543.0) | (653.6) | (1,714.5) | (418.3) | — | — | — | — | (156.9) | (82.9) | (52.0) | (28.5) | (19.0) |
| Income Tax Expense | 2.4 | 1.9 | 10.9 | 2.0 | 4.3 | 29.2 | 0.0 | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.4 | 0.4 |
| Net Income | ||||||||||||||||
| Net Income | (247.7) | 440.3 | (187.5) | (545.1) | (657.9) | (1,743.8) | (418.3) | (132.7) | (184.7) | (183.8) | (280.0) | (156.9) | (82.9) | (52.0) | (28.5) | (19.4) |
| Per Share | ||||||||||||||||
| Basic EPS | (1.51) | 2.72 | (1.23) | (5.41) | (8.42) | (23.44) | (7.27) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (1.51) | 2.58 | (1.23) | (5.41) | (8.42) | (23.44) | (7.27) | — | — | — | — | — | — | — | — | — |
| Revenue per Share | 2.51 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 164.6 | 162.0 | 152.2 | 100.8 | 78.2 | 74.4 | 57.6 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 164.6 | 173.1 | 152.2 | 100.8 | 78.2 | 74.4 | 57.6 | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | 480.4 | (200.4) | (525.3) | (615.7) | (1,673.9) | (411.8) | (114.9) | (165.8) | (161.9) | (260.6) | (151.3) | (79.3) | (49.8) | (28.0) | (20.0) |
| EBIT | (234.1) | 452.8 | (248.9) | (566.5) | (644.7) | (1,686.6) | (416.7) | (120.6) | (173.9) | (171.7) | (269.1) | (157.2) | (83.7) | (52.4) | (29.7) | (21.6) |
| Effective Tax Rate | -1.0% | — | — | -0.4% | -0.7% | -1.7% | 0.0% | — | — | — | — | 0.0% | 0.0% | -0.0% | -1.4% | -2.2% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.